Four Questions to Ask Before Hiring an R&D Partner

In pharma and biotech, the right R&D partner shapes a program as much as the science itself. CROs, CDOs and CDMOs aren't filling gaps anymore. They're contributing real scientific judgment at every stage, from early feasibility through late-stage development. That makes the choice of partner one of the most consequential decisions a program will make.

Credentials and case studies are a reasonable starting point, but they only show what a partner has already done. The real question is how they'll think, communicate and adapt over the life of the program. These four questions can give drug development and biotech leaders the insight they need to make the right decision.

1. Can you fill the role we actually need?

Pharma and biotech R&D programs don't all start from the same place and they don't all need the same thing from a partner. Some teams have strong internal capability and need targeted expertise to solve one specific problem or fill one defined gap. Others need a partner to step into a program already in motion (for example, after an acquisition, a funding interruption or a change in internal resources) and pick up where someone else left off. Both situations call for a partner who can adapt to the scope the program needs rather than defaulting to the role they're most comfortable playing. Getting clear on exactly what you need up front can help prevent a potential mismatch.

At Battelle, we can work with your team in whatever capacity is needed, whether that means performing a single small study, managing an entire program from start to finish, or stepping in mid-stream to get a program back on track. When a team already has strong technical capabilities or partial solutions in place, our job is to work alongside them. In other projects, we fill a larger role, providing comprehensive technical, strategic and program management support. In all cases, our approach is aligned to the client’s specific needs, goals and budget constraints.

2. How does your team handle setbacks?

Every pharma or biotech R&D program eventually runs into a snag: an assumption that doesn’t hold, early data that disappoints, a regulatory shift, a technical wrinkle nobody saw coming. How a partner talks about those moments says more than any case study can. The partners worth trusting are the ones who can describe a project that didn't go as planned, how they caught it and what they changed. Recognizing that something has shifted is one skill; having the depth to redesign around it is another, and it's the one that matters more.

At Battelle, that adaptability comes from a mix of technical depth and strategic experience. When new information changes the picture, our teams pivot and adjust the plan to keep the program on schedule and budget. Because Battelle's expertise spans well beyond any single program, we can reach back across the organization for new capability when a problem calls for it, whether that's a different technical discipline or deeper regulatory insight. We also look at how a shift in one part of a plan affects the rest, so a change to the science gets evaluated for what it means for regulatory strategy, timeline and budget, too. And every adjustment happens in collaboration with program leaders, with clear, honest communication every step of the way.

3. How do you think about derisking across the development cycle?

How a partner approaches risk timing tells you a lot about their experience level. Less experienced partners tend to default to a single, fully scoped plan because it's easier to manage and easier to sell upfront. More experienced ones are comfortable with a different conversation: staging the work, building in decision gates and proving out the fundamentals before committing resources to the next phase. The distinction matters because discovering a fundamental problem late in a program rarely costs just money. It can mean restarting work, resetting timelines, losing stakeholder confidence or missing a market window outright.

At Battelle, we design programs around decision gates rather than handing over one large plan and hoping it holds. Our teams identify the assumptions a program is most exposed to and build the earliest, leanest possible experiments to test them, so resources scale up only once the fundamentals are proven. That structure isn't about caution for its own sake. It's about spending a program's budget and timeline on the questions that actually determine whether it succeeds, in the order that provides the fastest and least expensive pathway to derisking.

4. How do you balance technical rigor with practical constraints?

Drug and biotech development sits at the intersection of scientific ambition, regulatory expectation, timeline pressure and finite resources. A partner who chases technical perfection without regard for budget or schedule creates problems just as real as one who moves fast without enough rigor behind it. The harder and more valuable skill is knowing where the line actually sits: which steps demand full rigor because the science or the regulatory pathway depends on it, and which ones can be simplified without putting the program at risk. That calibration only comes from experience, and a partner who can explain it specifically, rather than defaulting to either perfectionism or expediency, is showing you they've made this judgment call before and survived it.

At Battelle, we make that calibration explicit rather than leaving it as an unspoken judgment call. Our teams identify upfront which parts of a program are non-negotiable, often where regulatory risk or scientific validity is on the line, and where a simpler, faster approach is the smarter choice because added rigor wouldn't change the program's odds of success. We bring that reasoning to program leaders directly, laying out the trade-off and the "why" behind it rather than presenting a single path as the only option. The result is a program that spends its rigor where it counts and its speed where it can, instead of treating every decision as equally high stakes.

Choosing an R&D Partner for Pharma and Biotech

These four questions reveal how a partner actually thinks: whether they can flex to the role your program needs, absorb a setback and adapt the plan, build in the right decision points up front, and know when to hold the line and when to let go. A polished pitch tells you what a partner has built before. These questions tell you whether they can keep building alongside you once the plan inevitably changes.

At Battelle, we welcome these questions because they're the ones we ask ourselves at the start of every program. If you're choosing an R&D partner for your next phase of development, connect with our team to talk through how we'd approach the work.